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a turnover exceeding £1bn in 2009 (BIS, 2010). Using data derived from participant observation, this
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based medicine in the context of the 2010 United Kingdom (UK) Wounds UK conference/trade show,
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innovation and as a remover of solutions rather than a provider of them. The article is written in the
context of the trend towards increasing marketization and privatization in the UK National Health
Service (NHS).
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This article employs a case study methodwhich uses participant
observation to produce content analysis of a United Kingdom (UK)
health care conference. It is a method that has been used in medical
anthropology to report on similar sites of social contact in the
United States of America (USA) where medicine and marketing
come together (Applbaum, 2004; Sufrin, 2008). David Gray, Clinical
Nurse Specialist in Tissue Viability and Clinical Director of Wounds
UK identiﬁes the “vital” role the annual Wounds UK conference
plays in bringing together medical device companies and wound
care clinicians because, “the ﬁeld we work in is hugely driven by
innovation, which comes from industry” (Gray, 2010: np). The
conference is therefore a key site of what Lakoff (2007: p. 156)
terms in his ethnographic work on forms of knowledge in psychi-
atric practice in Argentina, “high contact”. That is a site for, “the
intensiﬁcation of relations between pharmaceutical [medical
device] companies and doctors [nurses]” (Lakoff, 2007: p. 156).
After a description of its methods, the article begins by outlining
the background to wound care in the UK and the current context of
clinical uncertainty. It describes the marketing of “innovation” and
the construction of the “evidence debate” at the Wounds UK 2010
conference. It then provides an analysis of observations made at-NC-ND license.this “high contact” event Lakoff (2007: p. 156), raising concerns
about the extent of industry inﬂuence in knowledge production
and the positioning of evidence based medicine in opposition to
clinical knowledge and as an obstacle to innovation. The analysis
draws on work in the anthropology of medicine, the sociology of
science and technology and the sociology of expectations.
Methods
The study emerged as part of a ﬁve-year programme of work
funded by the UK National Institute for Health Research (RP-PG-
0407-10428) (Lamb, Stubbs, Dumville, Cullum, & O’Meara, 2011).
Permission was granted for this aspect of the programme through
peer review and ethical scrutiny at the University of York. Obser-
vations of the conference were conﬁned to formal events rather
than social gatherings. No formal interviews were conducted. All
statements recorded were made in a public forum. The author
attended and introduced herself to others at the conference as
a researcher in the ﬁeld trying to better understand the contem-
porary context of wound care, aiming not to deceive or compromise
the privacy of those observed and interacted with (c.f. Shils, 1982;
Spicker, 2011). Contemporaneous ﬁeld notes and conference
documents form the core of the data set for this article (Emerson,
Fretz, & Shaw, 1995). Field notes were written unobtrusively over
three days as part of the normal activity of a conference-goer. Notes
on interactions were written from recall shortly after the events
took place. Commentary and reactions were bracketed in ﬁeld
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notes were later word processed and narrative description
expanded. Separate analytic notes were made during transcription
to identify themes and map ﬁelds of argument. All transcribed and
collected data were then reviewed and an additional set of
summary notes made. The author’s analysis is inevitably informed
by other aspects of the programme including interviewing patients,
shadowing clinicians, discussions with colleagues and an immer-
sion in the literature.
Background
Chronic, complex wounds, such as leg ulcers, pressure ulcers
and diabetic foot ulcers are common in the UK and throughout the
western (post-) industrialised nations (Graham, Harrison, Nelson,
Lorimer, & Fisher, 2003; Kaltenthaler, Withﬁeld, Walters,
Akehurst, & Paisley, 2001; Reiber, 1996). The prevention and
management of wounds poses a costly, unsolved health care chal-
lenge for these economies. Ageing populations living with chronic
conditions such as diabetes or venous disease which can lead to
chronic wounds, and those living with various degrees of immo-
bility, present a growing market for pharmaceutical and medical
device companies (Joyce & Loe, 2010). Direct to patient advertising
of prescription based products is illegal in the UK, somedical device
marketing strategies are targeted on clinicians (c.f. Browne,
Grocott, & Cowley, 2004).
Most of the care of people with chronic wounds in the UK is
undertaken by nurses with involvement from a wide range of
health and social care services and specialisms including tissue
viability, surgery, dermatology, care of the elderly, podiatry, phys-
iotherapy and occupational therapy. Wound management devices
prescribed in the UK National Health Service (NHS) are predomi-
nantly dressings but also include pressure relieving surfaces,
compression bandages, negative pressure devices and new
synthetic and bioengineered products such as tissue-engineered
skin substitutes. In what was once considered a “technologically
mature segment”, the wound care market is becoming a “hotbed of
innovation” as companies strive to develop products designed to
accomplish more than those already available in formularies
(Smith, 2009). This applies to ‘mundane’ technologies like dress-
ings whichmight be perceived as cheap and inert interventions. For
example, antimicrobial dressings containing silver ions which have
come to prominence over the last 10 years, and advanced wound
dressings designed to control the environment for wound healing;
to donate ﬂuid (hydrogels), maintain hydration (hydrocolloids), or
absorb wound exudate (alginates, foams) (BNF, 2011).
The 2009 prescription costs in England (community spend only,
i.e. not including hospital prescriptions) for products from the
wound management and dressing section of the British National
Formulary (BNF) were £138 million (DH, 2009). This puts expen-
diture on dressings and elastic bandages in the community setting
above that for vaccines/sera or drugs for dementia. Such large costs
are due to volume of use and the incorporation of increasingly
complex and expensive materials into dressings, for example silver
dressings on which £26 million was spent in 2009 (DH, 2009).
However, the extent to which the commodiﬁcation of medical
technologies in wound care is providing innovations that lead to
better health outcomes for patients remains uncertain and
evidence of the effectiveness of these interventions remains
limited. In addition, despite the ﬁnancial, social and personal costs
of chronic wounds, little is known about their number, nature and
care. Good quality up-to date epidemiological data are lacking
(Firth, Nelson, Hale, Hill, & Helliwell, 2010; Graham et al., 2003).
Clinical guidelines for wound care state that clinical judgement
must be used in the selection of the appropriate wound product(e.g. Steed et al., 2007). It is this clinical judgement that medical
device marketing and evidence based medicine seek to inform and
inﬂuence. The wound product supply chain is complex with local
providers developing their own formularies from those competing
products available in the BNF (e.g. Browne et al., 2004). A
comprehensive guide to product selection in wound care is
produced by the Mark Allen Group (a company involved in
publishing and communications in the health care, education,
consumer and business-to-business sectors) in associationwith the
Journal of Wound Care. Interspersed with advertising from manu-
facturers, this 258 page “bible of wound care” (Cowan, 2010: p. 5),
lists the products on the market with guidance on usage with the
caveat that its information is not a substitute for detailed product
knowledge: “Anyone working with wound care products has
a responsibility to familiarise themselves with the manufacturer’s
instructions and the most up-to date-evidence regarding their use”
(Cowan, 2010: p. 5).
Yet, research evidence to support clinicians’ choice of the
proliferating range of products available is scant (Polak, Clift,
Bower, & Sprange, 2008). Systematic reviews in wound manage-
ment which identify, critically appraise, and synthesize the
evidence produced in primary research, reveal a lack of high quality
studies and a predominance of small, underpowered and meth-
odologically ﬂawed randomized controlled trials (RCTs). One
reason for the lack of trials demonstrating treatment effectiveness
in this area is because most treatments for chronic wounds are
classiﬁed as devices rather than medicinal products. Unlike medi-
cines, devices are not automatically subject to a clinical trial. Under
the current European regulatory framework for evaluating and
regulating medical devices (CE marking), manufacturers are only
required to demonstrate safety and ﬁtness for purpose (Cohen &
Billinglsey, 2011; MHRA 2011). The evidence-base informing clin-
ical decision making is therefore very limited. There are exceptions,
for example it is recognised that compression bandaging is an
effective treatment for leg ulcers (O’Meara, Cullum, & Nelson, 2009)
and that people at high risk of developing pressure ulcers should
use higher-speciﬁcation foam mattresses rather than standard
hospital foam mattresses (McInnes, Jammali-Blasi, Bell-Syer,
Dumville, & Cullum, 2011).
As the end-payer for the NHS, the UK government has a strong
interest inmedical device product and price regulation. At the same
time, the ideological trend is towards increased marketization and
privatization of health care (DH, 2011). Pharmaceutical andmedical
devices companies are a signiﬁcant part of UK manufacturing
industry and there is powerful lobbying against additional regula-
tion (Abraham, 2002; Abraham & Davis, 2006; Di Mario, James,
Dudek, Sabate, & Degertekin, 2011). For example, in 2005, a UK
House of Commons Health Committee report on the inﬂuence of
the pharmaceutical industry reported that: “The Department of
Health has for too long optimistically assumed that the interests of
health and of the industry are as one. This may reﬂect the fact that
the Department sponsors the industry as well as looking after
health. The result is that the industry has been left to its own
devices for too long” (Health Committee, 2005: p. 3). In a recent bid
to, “capitalise on the [Coalition] government’s encouraging noises
about the sector” (InPharm.com, 2011), LifeSciencesUK has been
launched as a new lobbying group to improve joint working
between pharma, biotech, medical devices and diagnostics
companies.
Wound care management is one of the four largest segments of
the UK health technology sector, having fallen from its 2009 posi-
tion as the top health technology segment to 4th place in 2010 as
a consequence of a 14% drop in UK turnover in the wound care
market (BIS, 2010). It is nevertheless seen as part of a resilient
sector of the UK economy which exhibits strong export
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4000 of the UK health technology sector’s 55,000 workers.
Employment in the wound care segment increased by 6% during
2009e2010 (BIS, 2010).
Marketing innovation
Key opinion leaders and tissue viability nurses working closely
withwoundmanagement companies has been identiﬁed as amajor
factor driving the uptake of advanced wound management prod-
ucts (Faulkner, 2009: p. 79). Medical devices companies have
developed close relationships with nurses in the UK through the
sponsorship of conferences and continuing professional develop-
ment education and training. Manufacturers workwith wound care
practitioners to raise awareness of products and their use, promote
higher standards and advise on meeting the quality and produc-
tivity challenges set by health care reforms (e.g. Shorney & Rush,
2006; Whiting, Gleghorn, & Shorney, 2008).
Wounds UK describes itself as a wound care education company
providing conferences, events, roadshows and journals to clini-
cians. It is part of Schoﬁeld health care media which is in turn part
of Schoﬁeld Media Group, an international business-to-business
media company. Business-to-business marketing operates
between businesses rather than direct to the consumer. It involves
the promotion of goods and services that will help other companies
run. Wound care conferences are large, well attended events with
strong industry sponsorship and presence. The 2010 Wounds UK
conference includes a large exhibition with over 80 stands dis-
playing existing and new technologies in wound care prevention,
diagnostics and treatment. Plenary sessions, champagne receptions
and conference gala dinners are sponsored by medical device
companies.
Academic and medical conferences are fora for the rapid
dissemination of research ﬁndings, provide opportunities for
networking andare sites of argumentation. Argumentation is a social
and cooperative activity through which participants seek truth (or
victory) and resolve (or provoke) conﬂict (Walton, 2006). Whatever
their power plays, presenters and attendees at conferences test their
own and each other’s reasoning with doubt. Papers are peer
reviewed and publication, often the only tangible evidence that
research has been done, is sought. Publications should provide
sufﬁcient information to allow full evaluation of presented data
(Langley & Parkinson, 2009). An investigation into the publication of
research from international wound care conferences has shown that
publication is highly unlikely and less likely compared with other
medical specialities (Dumville, Petherick, & Cullum, 2008). Lack of
publication fromwounds conferences raises questions about meth-
odological quality and selective presentation bias (Dumville et al.,
2008).
Industry led conferences engaged in business-to-business
marketing (the businesses being medical device companies and the
NHS) have a vested interest in promoting products. The marketing
bias at the 2010Wounds UK conference is evident in the selection of
presentations at company sponsored plenary sessions which seek
to present particular products in the best possible light, with
clinician satisfaction standing as evidence of effectiveness. There
are plenary sessions promoting hosiery for compression, “pain-
free” dressings, low frequency ultrasound therapy, and most
frequently, innovations in the diagnosis, treatment and assessment
of wound infection.
For example, observed at this conference in a plenary promoting
devices for delivering, “safe and innovative choice for patients less
tolerant of compression”, a clinical nurse specialist in cellulitis
describes, “a duty to evaluate new bandages that come along”, and
her use of a new two layer reduced compression kit. The kit isexplained to an audience aware of the evidence that compression
helps improve venous return and so treats the venous insufﬁciency
that contributes to ulcer formation. Current systematic reviews and
clinical guidelines recommend four layer bandaging as the most
clinically effective bandaging treatment for venous leg ulcers in
those that can tolerate high compression (O’Meara et al., 2009).
Newer two layer bandaging systems like this kit have become
available but there are as yet no RCTs to show that these are as
effective as, or more effective than, the standard treatment. The
presenting nurse specialist explains that the new kit was “trialled”
on six patients with the help of a company rep. On the basis of her
satisfaction with the product, she does not identify the need for
more substantive research but urges the audience to go to the stand
to read all the (market) research they have available and to, “ensure
formularies don’t remain static” (Beasley & Blenman, 2010: np). In
support of the same product another nurse speaker claims to be
a sceptic who had said she would eat her hat if the new bandaging
system worked. After a show of slides demonstrating changes in
wounds she has treated with the kit, she brings out a little edible
hat and takes a bite out of it (Beasley & Blenman, 2010: np).
As well as presentations demonstrating success in the hands-on
use of the device promoted, there are presentations to show that
“fundamental studies” (laboratory work) can help gain a better
understanding of how products work. For example, a speaker
presents “highly controlled” in vitro experiments which ﬁnd that
the dressing being promoted compares favourably against two
other named dressings (Davies, 2010: np). Questions from the ﬂoor
at the end of these plenary sessions do not address methodological
issues. Rather than conference presentations where reasoning is
subject to scrutiny and doubt, such presentations are more like
infomercials, advertisements that with the exception of hat-eating,
downplay the obvious features of advertising in favour of a more
technical information giving genre.
New alternatives to antimicrobial silver dressings are promoted
in the wake of the publicly-funded VULCAN trial (Michaels et al.,
2009) which found no evidence of a difference in healing efﬁcacy
between silver dressings and low adherent, non-antimicrobial
dressings in venous leg ulcers. Plenary speakers state that clini-
cians have been criticised for their over-use of antimicrobials but
that it is not the products (or the clinicians) that are at fault. They go
on to say that there are more treatments in wound care than
clinicians knowwhat to do with, but what is missing are diagnostic
and assessment tools that can better direct the choice of what
product to use at which point in the wound healing process.
Diagnostics inwound care are described as currently amatter of,
“reading signs and symptoms”, “eyeballing and guessing”, “a
process of elimination” and “stabs in the dark” (Snyder, Harding, &
Barrett, 2010: np). The development of diagnostic tools promises
more professional credibility; “we need to move our game
upwards” (Snyder et al., 2010: np). The production of these tools
rests on an understanding of wound healing at a cellular level and
identifying markers or indicators of infection. This hinges on a yet
to be evidenced argument that infection and bioﬁlms (the idea that
bacteria aggregate to form a tough resistant layer) play an impor-
tant part in chronic or, “non-healing” wounds.
As in the marketing of pharmaceuticals, there are few genuinely
paradigm busting wound care device innovations and many
product-line extensions which are ‘innovative’ only in that they
work to differentiate a product from others on the market (Angell,
2005). These introduce small deviations of what is essentially the
same product, changing little more than surface features or minor
attributes. When there are few new ideas and few proven marginal
beneﬁts in a commercial sector, one response is more marketing
(Sharp & Dawes, 2001). The conference is saturated with wound
treatment advertisements many of which have been shown to be
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made. For example, where research is cited in wound treatment
adverts, 56% of claims made were not supported by the cited
research article (Dumville, Petherick, O’Meara, Raynor, & Cullum,
2009).
Sugared solutions
Once the exhibition has opened, conference goers must walk
through the entire show-room area in order to reach tea, coffee and
lunch. Alternatively, it is possible to stop off and have tea, coffee and
cakes at many of the wound product marketing stands that are
staffed with baristas. Or, there are stands with juice bars, ice cream
machines and chocolate fountains. Many offer sweets and one is
fully dressed as a sweet shop.
Clinicians (predominantly nurses) have been encouraged by
speakers at the conference to exercise their duty to make an
informed choice on behalf of their patients and this is a chance to do
so. The exhibition addresses its attendees through rational,
emotional and sensual means. There is a lot to look at and touch.
There are free samples, educational brochures and opportunities to
have amassage or amanicure; eat ice-creamand sweets; admire the
stockings on dancing canecan mannequin legs, or the muscles on
a be-glittered blue genie, or spot Elvis: “Beware of imitations.
There’s only one Elvis and only one range of .products”. This is
a much more informal, sociable site of “high contact” than the
conference auditorium (Lakoff, 2007: p 156). Sales reps take over
from sponsored conference speakers as they “sell without selling”
(Oldani, 2004: p. 334). Nomoney changes hands but there are lots of
free samples in boutique style shopping bags. Visitors to exhibition
stands are asked about their use of the product on display and are
offered samples, support and encouragement to try something new.
The stimulus to ‘buy’ is perhaps to ease the distress of the
painful recalcitrant wounds that clinicians have to deal with every
day, which have been represented so graphically throughout the
conference in case studies accompanied by close-up photographs of
wounds. Patients are not present at the conference but patient
success stories are at the heart of the exchanges between clinicians
and reps. Individual stories of difﬁcult cases and obstacles to be
overcome are exchanged in one-on-one encounters in stands that
market material solutions for use in practice.
Alienating evidence based medicine
Wounds UK have attempted to invite specialists in the ﬁeld of
wounds evidence from the Cochrane Wounds Group, part of the
Cochrane Collaboration, an international non-proﬁt, independent
research publishing organization that aims to improve access to
health care research ﬁndings (CWG, 2011), to speak at a research/
audit session titled: “What is acceptable evidence for medical
devices in the wound care ﬁeld” (Harding, White, & Jeffrey, 2010:
np). Nobody was available to attend. The chair of the session invites
the audience to make their own judgement on the signiﬁcance of
this absence, represented by two empty seats which have been left
on the speakers’ platform. The evidence debate is introduced as
central to the conference because it affects which products will be
available to clinicians. The session contains presentations critical of,
“an academic led approach with Cochrane Wounds Group in the
vanguard; an unelected body to advise and pontiﬁcate to you, the
practitioners” (Harding et al., 2010: np). For example, speakers are
unimpressed by the ﬁndings of a systematic review (Chaby et al.,
2007) which is said to dispute a central tenet of modern wound
care, moist wound healing.
Rather than allowing wounds to dry out and form scabs to
promote healing, George D. Winter (1962) found that wounds inpigs healed faster if kept moist. Many dressing products on the
market are therefore developed for the healing of chronic wounds
through moist wound therapy. However, the Chaby et al. (2007)
review found only weak evidence on the clinical efﬁcacy of
modern dressings, except hydrocolloids, for healing wounds in
comparison with saline or parafﬁn gauze. In terms of general
performance, none of the modern dressings were found to be any
more effective than any other, including saline or parafﬁn gauze.
In the light of this review, one speaker asks whether we are
going forward or backwards, especially given that silver dressings
are also, “under considerable attack”. He states that the work of key
ﬁgures in evidence based medicine has helped to place RCTs at the
top of the hierarchy of evidence but, “what about non-RCT
evidence? Is it irrelevant? Who is inﬂuencing policy? Who is
inﬂuencing you?” (Harding et al., 2010: np). The speaker cites
Michael Rawlins (2008) as saying hierarchies of evidence are illu-
sory, observations are as important and judgements are an essen-
tial ingredient. It is not enough to, “type in wound care in PubMed
and think that’s OK, that’s enough” (Harding et al., 2010: np).
All speakers in the debate argue that high level statistical
analysis is being prioritised over clinical experience and that the
broader evidence base and the real needs of clinicians and patients
are being side-lined. They discuss guidelines for clinical practice
that provide a grading system for the quality of evidence on which
guidance is based, the GRADE (2004) system and the AGREE system
(2001).
AGREE (Appraisal of Guidelines Research & Evaluation) is an
international collaboration of researchers and policy makers
seeking to improve the quality and effectiveness of clinical practice
guidelines by establishing a shared framework for their develop-
ment, reporting and assessment. The AGREE system arose as
a response to ﬁnding many clinical guidelines to be industry
sponsored with limited objectivity. The developers of the GRADE
(Grades of Recommendation, Assessment, Development and Eval-
uation) system wanted to emphasize consistency in the rating of
guidelines, as well as incorporating and distinguishing between,
the ‘strength’ of each guideline and the ‘quality’ of the underlying
studies upon which it is based. Both systems rank ‘very low’ any
evidence other than randomized trials and observational studies.
The conference is told that there will not be rapid product
development if companies have to do RCTs, but nevertheless
companies must provide evidence that yields high strength
recommendations in the GRADE system, otherwise clinicians will
be left with the least costly dressing, as has been recommended in
the recent National Prescribing Centre MeReC Bulletin (2010). This
refers to a NHS document that states:
There is no robust clinical evidence that dressings containing
antimicrobials (e.g. silver, iodine or honey) are more effective
than unmedicated dressings for the prevention or treatment of
wound infection (MeRec, 2010: p. 1).
Unless the use of a speciﬁc dressing can be adequately justiﬁed
on clinical grounds, it would seem appropriate for NHS health
professionals to routinely choose the least costly dressing.
(MeRec, 2010: p. 1).
One speaker describes the “evidence pyramid”, stating that, “in
wounds, real life is at the bottom of the pyramid” (Harding et al.,
2010: np). He claims that all evidence other than RCTs is being
ignored and that one does not have to have any clinical knowledge
to conduct systematic reviews. He states that they are oftenwritten
by epidemiologists and statisticians with no day to day knowledge
and experience of clinical practice; “clinical knowledge is a detri-
ment” (Harding et al., 2010: np). References to the “real world” of
clinical practice get applause. He reminds the audience that
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and also advocates the GRADE (2004) systemwhich states that it is
possible to make strong recommendations from low quality
evidence. Cochrane reviews are criticised for merely reiterating
that there is, “not enough evidence” and for asserting that the
only measure of success is a healed wound: “some of my patients
never heal.each patient is a one-on-one experiment. Cochrane
[Wounds] Group don’t accept these patients exist” (Harding et al.,
2010: np).
There follow questions and comments from the ﬂoor which
express concerns about lack of funding for products and services on
the basis of lack of evidence: “Cochrane are constraining what we
get”. One of the panel speakers replies that evidence based medi-
cine is backﬁring. Cochrane is a hindrance. Many different products
have been developed over the years, but how are clinicians to get
these into their formularies if the evidence is not there? Clinicians
need “tools not rules” (Harding et al., 2010: np). Other concerns
from the ﬂoor are the professional credibility of tissue viability
nursing, the need to attend to the subjective aswell as the scientiﬁc,
patients in RCTs not being representative of typical wounds
patients and the difﬁculties of getting informed consent from
elderly people. The panel comments on the difﬁculty of designing
trials inwound care and their experience of research governance as
an obstacle, “it’s enough to make you give up on RCTs.” The session
ends with a caution against squashing innovation and an amelio-
rating comment from David Gray, the Clinical Director of Wounds
UK urging the conference not to, “bash Cochrane; teach them how
to do it properly”.
Conclusion
Concepts of scientiﬁc research, market commodity and
commercial competition inform the marketing strategies on which
claims about wound product safety and efﬁcacy are based. It is
perhaps a category mistake to approach this event as one would an
academic conference when it is in effect a trade fair. There are no
alternative, industry-free scientiﬁc conferences in this sector.
Despite the centrality of the exhibition and claims about cost
effectiveness, the economic end points of the conference are
downplayed. The yield of marketing interactions is proﬁt but the
treatments that proﬁt industry may not provide the outcomes that
mean most to patients.
Those attempting to promote marketing practices for use within
the NHS as part of increasing patient choice acknowledge that for
clinicians the practice ofmarketing is often viewed as, “anathema to
the ethos of theNHS” (TheChartered Institute ofMarketing, 2008: p.
i; see also Leys & Player, 2011). Although there may be fewer “high
contact” sites in the publicly-funded UK National Health Service
(NHS) than in more heavily commercialised health services, the UK
policy trend is towards increasing competition, commercialisation
and marketization (Pollock, 2004). Clinicians are intermediaries in
the medical device marketing channel that delivers products to
patients (Applbaum, 2009). In order to keep products moving,
industry must negotiate the barriers that divide conventions in
medical research and practice from marketing objectives
(Applbaum, 2009). It is important to note that the embracing of
industry involvement at this conference may not be representative
of the whole sector; clinicians who are critical may stay away.
The knowledge, innovation and ‘education’ produced and
imparted at the conference are not disinterested. Although there
are references to ‘holistic’ assessment in presentations by nurses,
the idea that patient health might depend on a host of factors
outside medical technology and pharmaceutical innovations is not
aired. The focus is ﬁrmly on mechanical and pharmaceutical solu-
tions to wound care problems through medical device innovation.The conference and its exhibition can be seen as part of, “the
business of expectations” (Brown, Rappert, & Webster, 2000;
Pollock & Williams, 2010). The conference and its exhibition give
life and meaning to products that provide hope, if not proof, of
effectiveness and fuel expectation (a market) in future technolog-
ical solutions.
Clinicians attending the conference state that they are under-
valued and seek to have their practical expertise acknowledged.
The development of professionalism through the hopeful and
heroic use of unproven but innovative treatments takes place
against a backdrop of late capitalist, post-credit crunch austerity;
a time of uncertainty about what the future holds for clinicians who
face job insecurity, health service rationing and reorganisation and
growing levels of demand. Systematic reviews that ﬁnd that there is
a lack of evidence of treatment efﬁcacy are not an answer to the
immediate needs of clinicians called on to deliver solutions for
patients and are associated with rationing. Having a renewable
range of therapies available in the cupboard means that at least
clinicians are able to provide some form of purported solution for
any patient at any given time.
Evidence based medicine has been perceived as promising/
threatening to standardise clinical decision making and so chal-
lenges the clinical tradition of professional autonomy (Timmermans
& Berg, 2003). It has been seen as part of the displacement of trust in
experts by trust in processes, procedures and statistical measure-
ment because, although clinical judgement is involved (Sackett,
Rosenberg, Muir Gray, Haynes, & Richardson, 1997), judging treat-
ment effects in trials is fundamentally statistical and epidemiolog-
ical (Porter, 1995). The audible consensus at this conference
positioned thosewho insist on RCTs and systematic reviews as non-
clinical technocrats and obstacles to innovation. Whereas, in vitro
knowledge produced in laboratories is presented as fundamental
and easily transferable to clinical practice (e.g. Davies, 2010;
Wiegand, 2010), knowledge produced in RCTs and systematic
reviews is presented as unrelated to the ‘real world’ of clinical
practice.
The Cochrane Collaboration is portrayed as in the service of
ration-focused ‘paymasters’ and those who would proscribe or
curtail individual powers of clinical decision making. Systematic
reviews highlight that the most knowledgeable and experienced
clinicians in wound care are faced with an evidence gap. Where
clear evidence does not exist, clinicians are left with uncertainty
and are reliant on expert consensus. Such consensus is informed by
clinical experience of using pharmaceutical and technological tools.
Even with the acknowledged need for evidence and limitations of
“eyeballing and guessing”, little critical attention is paid at the
conference to the problem that clinical observations can be
misleading. Conference plenary presentations, posters and leaﬂets
are replete with claims of efﬁcacy. However, in the absence of
rigorous independent peer review and publication, many of these
can be seen as artefacts of what Sismondo (2009) calls “corporate
science”, the production of investigations designed to look like
academic work in order to further marketing messages.
Meanwhile wound care treatments are not being adequately
researched for effectiveness. Clinical guidelines in areas of wounds
research have been based on the results of animal studies (Robson
et al., 2006) and there have been calls for the abandonment of the
RCT and of systematic reviews in wound care (Gottrup, 2006;
Leaper, 2009). Instead of ﬁlling the evidence gap with evidence,
medical device companies market the promise of solutions through
endless wound management innovation. Once a device is launched
onto the market, the incentives to conduct quality research on
clinical use are reduced because research is expensive and seeking
proof of efﬁcacy threatens to remove lucrative products/solutions
from the market.
M. Madden / Social Science & Medicine 74 (2012) 2046e2052 2051The conference promotes a market in ‘advanced wound care’.
Pricing for innovative new-generation products represents
a signiﬁcant premium compared to existing wound care products.
As consumers we are already attuned to the ideas that ‘you get
what you pay for’ and that new is improved and therefore better.
Unfortunately, until efﬁcacy is proven, new technologies are as
likely to be inferior as they are superior to existing technologies
(Chalmers, 1995). The term ‘innovation’ requires interrogation
(Abraham & Davis, 2011; Van Lente, 2000) and in particular the
extent to which innovation is present in the potential of a tech-
nology and/or in the marketing strategy used to promote it. For
example wound dressings which usefully manage symptoms such
as wound exudates or odour can bemarketed and priced as curative
solutions. Chronic wounds can be seen as symptomatic of under-
lying conditions and perhaps research might be better focused on
tackling these underlying conditions and less on innovations for
symptomatic wound care.
The General Medical Council has guidance which insists that
doctors must work with colleagues and patients to help “resolve
uncertainties about the effects of treatments” (GMC, 2010: 14f). It is
perhaps a case of shooting the messenger to blame reviewers
rather than clinicians, researchers, medical device companies and
other stakeholders in this area for the lack of well reported,
methodologically sound trials and other high quality research. The
idea that wound care RCTs are uniquely difﬁcult to undertake has
been disputed by those who have successfully conducted trials in
this area (see Ashby et al., 2010); wounds are not rare and the
outcomes are observable.
Conferences in the wounds sector are industry led sites of “high
contact” (Lakoff, 2007: p. 156). Studying high contact sites can
provide an insight into how ‘the real world’ of clinicians is engaged
with and utilised in ‘market logics’. Successfully marketing product
innovations to clinicians requires an understanding of “howdoctors
[and nurses] think” (Montgomery, 2006). A systematic review of
the diffusion of innovations in service organisations highlights the
importance of understanding social inﬂuence and the networks
through which it operates (Greenhalgh, Robert, Macfarlane, Bate, &
Kyriakidou, 2004). Research from the USA indicates that nurses
view marketing activities as educational and beneﬁcial. They
perceive other providers, but not themselves as being susceptible to
inﬂuence (Crigger, Barnes, Junko, Rahal, & Sheek, 2009). However,
there is evidence that promotional activity does inﬂuence doctors’
prescribing behaviour (Elliott, 2010; Oldani, 2004; Prosser, Almod,
& Walley, 2003; Wazana, 2000). There is a need for further
research on the inﬂuence of marketing and potential conﬂicts of
interest within UK wound care. There is little social scientiﬁc work
in this ﬁeld. The gendered marketing of technology in this sector
and the “doctor-nurse game” (Radcliffe, 2000; Stein, 1967) played
out between predominantly male doctor opinion leaders and
predominantly female nurses also warrant critical attention.
In addition perhaps the problems that wound care clinicians
face in attempting to operate in a research-informed fashion are not
being sufﬁciently addressed (c.f. Oswald & Bateman, 2000). For
example, Haynes (1990) and Lomas (2007) have argued that much
of the biomedical literature for clinical decision making is designed
for communication between scientists and not for dissemination of
practicalities. Efforts are being made to enhance and promote
“evidence based nursing” (e.g. Thompson, Cullum, McGaughan,
Sheldon, & Raynor, 2004) and clinician statistical literacy (c.f.
Gigerenzer, 2002). Given the positioning of clinicians as gate-
keepers in the commercialisation of health care, citizens may also
like to see clinicians equipped with training in skills to critique the
marketing strategies and materials targeted at them.
Wound care by itself does not really exist as a clinical speciality.
Through this clinician focused conference and its tradepublications, the medical device industry brings a disparate market
together. Signiﬁcant time, resources and skills are put into devel-
oping and supporting that market and in communicating
marketing messages. As well as products to use with patients, the
conference provides pressurised and undervalued clinicians with
light relief in the form of some banter, a cup of coffee, a massage,
a manicure, sweets, attention, ‘care’. However, the short term
comforts of clinician sugar may not result in long term patient
health gain.
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